Orfeas Liangos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Orfeas Liangos has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Bertrand L. Jaber
The Kidney and Dialysis Research Laboratory, Division of Nephrology, Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States of America
2 shared publications- Bertrand L. Jaber
Department of Medicine
2 shared publications Francesco Addabbo
Division of Nephrology, New York Medical College, Valhalla, New York, United States of America
2 shared publications- Amir Abdollahi
Center of Cancer Systems Biology, Steward Research & Specialty Projects Corp., St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States of America
1 shared publication Arndt Petermann
1 shared publication- Brian J G Pereira
Division of Nephrology, New England Medical Center, Boston, MA
1 shared publication
Latest Publications
- 1 September 2016
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 45 (9) , 331-337
Atypische AL-Amyloidose mit Erythrozytenzylindern im Urinsediment
- 1 September 2016
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 45 (9) , 331-337
Atypische AL-Amyloidose mit Erythrozytenzylindern im Urinsediment
- Open Access
- 23 September 2015
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology – Case Studies
- Vol. 3, 19-24
Atypical case of AL amyloidosis with urinary erythrocyte casts
We present the case of a 73-year-old man who developed an acute, severe febrile illness with multiorgan dysfunction, featuring renal failure, nephrotic-range proteinuria, microhematuria, and a skin rash. Numerous erythrocyte casts were found on urine microscopy. Typically, the finding of urinary erythrocyte casts indicates the presence of an underlying glomerular inflammatory disease. However, on renal biopsy, only amyloid light-chain (AL) amyloidosis and tubular injury were the predominant findings with no signs of glomerular or vascular inflammation. Photomicrographs of urinary sediment as well as renal biopsy histopathology of the presented case are shown. The unusual combination of findings, is then discussed in light of the existing literature on renal amyloidosis as well as erythrocyte casts in conditions other than glomerulonephritis.
- 23 September 2015
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology – Case Studies
- Vol. 3, 19-24
Open AccessAtypical case of AL amyloidosis with urinary erythrocyte casts
We present the case of a 73-year-old man who developed an acute, severe febrile illness with multiorgan dysfunction, featuring renal failure, nephrotic-range proteinuria, microhematuria, and a skin rash. Numerous erythrocyte casts were found on urine microscopy. Typically, the finding of urinary erythrocyte casts indicates the presence of an underlying glomerular inflammatory disease. However, on renal biopsy, only amyloid light-chain (AL) amyloidosis and tubular injury were the predominant findings with no signs of glomerular or vascular inflammation. Photomicrographs of urinary sediment as well as renal biopsy histopathology of the presented case are shown. The unusual combination of findings, is then discussed in light of the existing literature on renal amyloidosis as well as erythrocyte casts in conditions other than glomerulonephritis.
- 21 April 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biomarkers
- Vol. 4 (1) , 53-59
Calcimimetic Drugs and Biomarkers
The calcium-sensing receptor is expressed almost ubiquitously throughout the human body, and is essential for calcium homeostasis and is involved in several disease pathomechanisms. Mainly in nephrology, therapeutic compounds acting on the receptor are already in use in clinical routine practice. The era of calcimimetic therapy, which commenced 10 years ago with the approval of the first-in-class compound cinacalcet HCl, has recently entered into a new phase with the arrival of velcalcetide (AMG416). Since both compounds bind to different sites at the receptor molecule, genetic polymorphism panels could conceivably play a role in future for the prediction of the best choice for any given patient. If velcalcetide, which has currently just passed phase-III-trials, is also approved for therapeutic use, this will increase the spectrum of choices and the clinician will have to make decisions about which calcimimetic drug to give to which patient. This decision would probably have to be based on various considerations including biomarkers. This article summarizes the present situation regarding patents on biomarkers dealing with the calcium-sensing receptor and genetic polymorphisms.
- 21 April 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biomarkers
- Vol. 4 (1) , 53-59
Calcimimetic Drugs and Biomarkers
The calcium-sensing receptor is expressed almost ubiquitously throughout the human body, and is essential for calcium homeostasis and is involved in several disease pathomechanisms. Mainly in nephrology, therapeutic compounds acting on the receptor are already in use in clinical routine practice. The era of calcimimetic therapy, which commenced 10 years ago with the approval of the first-in-class compound cinacalcet HCl, has recently entered into a new phase with the arrival of velcalcetide (AMG416). Since both compounds bind to different sites at the receptor molecule, genetic polymorphism panels could conceivably play a role in future for the prediction of the best choice for any given patient. If velcalcetide, which has currently just passed phase-III-trials, is also approved for therapeutic use, this will increase the spectrum of choices and the clinician will have to make decisions about which calcimimetic drug to give to which patient. This decision would probably have to be based on various considerations including biomarkers. This article summarizes the present situation regarding patents on biomarkers dealing with the calcium-sensing receptor and genetic polymorphisms.
- 1 January 2013
- Published by Springer Nature
- p. 427-480
Dialyzer Structure and Membrane Biocompatibility
- 1 January 2013
- Published by Springer Nature
- p. 427-480
Dialyzer Structure and Membrane Biocompatibility
- 1 March 2012
- Vol. 64 (1) , 51-62
Drugs and AKI.
Acute kidney injury is a common complication in hospitalized patients and is associated with substantially increased morbidity and mortality. Frequently, it is caused by impaired renal perfusion, ischemia and reperfusion injury, sepsis or urinary tract obstruction, but often its etiology is multifactorial. In this context, the contribution of nephrotoxic medications to the development of AKI plays an important role. This review begins with an attempt to evaluate the importance of drug-related acute kidney injury in general. Then, a selected list of 7 classes of drugs or compounds, namely aminoglycosides, aristolochic acid, cytostatic drugs, nonsteroidal anti-inflammatory drugs, osmotic agents, radiocontrast, and phosphate salts are discussed in depth, including their epidemiology, pathophysiology, clinical features and treatment. While not attempting to be exhaustive, this review attempts to provide an overview with additional in-depth information on certain classes of drugs that are either of general importance or have recently emerged in the literature.
- 1 March 2012
- Vol. 64 (1) , 51-62
Drugs and AKI.
Acute kidney injury is a common complication in hospitalized patients and is associated with substantially increased morbidity and mortality. Frequently, it is caused by impaired renal perfusion, ischemia and reperfusion injury, sepsis or urinary tract obstruction, but often its etiology is multifactorial. In this context, the contribution of nephrotoxic medications to the development of AKI plays an important role. This review begins with an attempt to evaluate the importance of drug-related acute kidney injury in general. Then, a selected list of 7 classes of drugs or compounds, namely aminoglycosides, aristolochic acid, cytostatic drugs, nonsteroidal anti-inflammatory drugs, osmotic agents, radiocontrast, and phosphate salts are discussed in depth, including their epidemiology, pathophysiology, clinical features and treatment. While not attempting to be exhaustive, this review attempts to provide an overview with additional in-depth information on certain classes of drugs that are either of general importance or have recently emerged in the literature.
- Open Access
- 27 October 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (10) , e13658
Whole Blood Transcriptomics in Cardiac Surgery Identifies a Gene Regulatory Network Connecting Ischemia Reperfusion with Systemic Inflammation
Cardiac surgery with cardiopulmonary bypass (CS/CPB) is associated with increased risk for postoperative complications causing substantial morbidity and mortality. To identify the molecular mechanisms underlying CS/CPB-induced pathophysiology we employed an integrative systems biology approach using the whole blood transcriptome as the sentinel organ. Total RNA was isolated and globin mRNA depleted from whole blood samples prospectively collected from 10 patients at time points prior (0), 2 and 24 hours following CS/CPB. Genome-wide transcriptional analysis revealed differential expression of 610 genes after CS/CPB (phub nodes of the identified network included key sensors of ischemia-reperfusion (HIF-1alpha and C/EBPbeta). Activation of this network initiated a concerted inflammatory response via upregulation of TLR-4/5, IL1R2/IL1RAP, IL6, IL18/IL18R1/IL18RAP, MMP9, HGF/HGFR, CalgranulinA/B, and coagulation factors F5/F12 among others. Differential regulation of 13 candidate genes including novel, not hitherto CS/CBP-associated genes, such as PTX3, PGK1 and Resistin, was confirmed using real-time quantitative RT-PCR. In support of the mRNA data, differential expression of MMP9, MIP1alpha and MIP1beta plasma proteins was further confirmed in 34 additional patients. Analysis of blood transcriptome uncovered critical signaling pathways governing the CS/CPB-induced pathophysiology. The molecular signaling underlying ischemia reperfusion and inflammatory response is highly intertwined and includes pro-inflammatory as well as cardioprotective elements. The herein identified candidate genes and pathways may provide promising prognostic biomarker and therapeutic targets.
- 27 October 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (10) , e13658
Open AccessWhole Blood Transcriptomics in Cardiac Surgery Identifies a Gene Regulatory Network Connecting Ischemia Reperfusion with Systemic Inflammation
Cardiac surgery with cardiopulmonary bypass (CS/CPB) is associated with increased risk for postoperative complications causing substantial morbidity and mortality. To identify the molecular mechanisms underlying CS/CPB-induced pathophysiology we employed an integrative systems biology approach using the whole blood transcriptome as the sentinel organ. Total RNA was isolated and globin mRNA depleted from whole blood samples prospectively collected from 10 patients at time points prior (0), 2 and 24 hours following CS/CPB. Genome-wide transcriptional analysis revealed differential expression of 610 genes after CS/CPB (phub nodes of the identified network included key sensors of ischemia-reperfusion (HIF-1alpha and C/EBPbeta). Activation of this network initiated a concerted inflammatory response via upregulation of TLR-4/5, IL1R2/IL1RAP, IL6, IL18/IL18R1/IL18RAP, MMP9, HGF/HGFR, CalgranulinA/B, and coagulation factors F5/F12 among others. Differential regulation of 13 candidate genes including novel, not hitherto CS/CBP-associated genes, such as PTX3, PGK1 and Resistin, was confirmed using real-time quantitative RT-PCR. In support of the mRNA data, differential expression of MMP9, MIP1alpha and MIP1beta plasma proteins was further confirmed in 34 additional patients. Analysis of blood transcriptome uncovered critical signaling pathways governing the CS/CPB-induced pathophysiology. The molecular signaling underlying ischemia reperfusion and inflammatory response is highly intertwined and includes pro-inflammatory as well as cardioprotective elements. The herein identified candidate genes and pathways may provide promising prognostic biomarker and therapeutic targets.
- 30 April 2010
- Published by Taylor & Francis in Biomarkers
- Vol. 15 (5) , 436-445
Exploration of disease mechanism in acute kidney injury using a multiplex bead array assay: a nested case–control pilot study
Background: Acute kidney injury (AKI) following cardiac surgery with cardiopulmonary bypass (CPB) causes increased morbidity and mortality. Objective: To evaluate the plasma profile of biomarkers potentially involved in AKI development following CPB. Methods: In a nested case–control study, plasma levels of 27 biomarkers in 11 AKI cases were compared with 25 controls. Results: Pre-CPB, plasma levels of epidermal growth factor and macrophage inflammatory protein-1β, 2 h following CPB, soluble vascular cell adhesion molecule-1 (sVCAM-1), fractalkine and macrophage inflammatory protein-1α, and at later time points, sVCAM-1 and interleukin-6 were associated with AKI. Conclusion: Biomarkers associated with AKI following CPB may merit further study.
- 30 April 2010
- Published by Taylor & Francis in Biomarkers
- Vol. 15 (5) , 436-445
Exploration of disease mechanism in acute kidney injury using a multiplex bead array assay: a nested case–control pilot study
Background: Acute kidney injury (AKI) following cardiac surgery with cardiopulmonary bypass (CPB) causes increased morbidity and mortality. Objective: To evaluate the plasma profile of biomarkers potentially involved in AKI development following CPB. Methods: In a nested case–control study, plasma levels of 27 biomarkers in 11 AKI cases were compared with 25 controls. Results: Pre-CPB, plasma levels of epidermal growth factor and macrophage inflammatory protein-1β, 2 h following CPB, soluble vascular cell adhesion molecule-1 (sVCAM-1), fractalkine and macrophage inflammatory protein-1α, and at later time points, sVCAM-1 and interleukin-6 were associated with AKI. Conclusion: Biomarkers associated with AKI following CPB may merit further study.
- 1 January 2004
- Vol. 144, 63-75
Cytokine single nucleotide polymorphism. Role in acute renal failure.
Although the pathogenesis of ARF is heterogeneous and results from a combination of different environmental influences and host responses, there is overwhelming data to suggest a common pathway that involves pro- and anti-inflammatory molecules, which in turn, determines the extent of tissue injury. The number of recognized cytokine gene polymorphisms is growing daily. The development of cytokine gene mapping may help identify patients in whom an excessive systemic inflammatory response may follow a therapeutic intervention (e.g. CABG, contrast administration), and who may be at increased risk for developing acute organ dysfunction. Through these advances, tools may be developed to better understand, prevent and treat ARF. Genetic epidemiology studies may help characterize the importance of genetic markers in the development of ARF. This would require large prospective cohort studies aimed at examining associations between genetic markers, urinary (urine KIM-1 and NAG) and circulating (serum creatinine) markers of kidney injury. Once firmly established, the association of a particular genetic profile and outcome could be used to risk stratify patients for the development of ARF (fig. 4). Ultimately, cytokine-modulating therapies could be employed on the basis of genotypic risk stratification with the goal to prevent kidney injury or minimize its deleterious effects on patient outcome.
- 1 January 2004
- Vol. 144, 63-75
Cytokine single nucleotide polymorphism. Role in acute renal failure.
Although the pathogenesis of ARF is heterogeneous and results from a combination of different environmental influences and host responses, there is overwhelming data to suggest a common pathway that involves pro- and anti-inflammatory molecules, which in turn, determines the extent of tissue injury. The number of recognized cytokine gene polymorphisms is growing daily. The development of cytokine gene mapping may help identify patients in whom an excessive systemic inflammatory response may follow a therapeutic intervention (e.g. CABG, contrast administration), and who may be at increased risk for developing acute organ dysfunction. Through these advances, tools may be developed to better understand, prevent and treat ARF. Genetic epidemiology studies may help characterize the importance of genetic markers in the development of ARF. This would require large prospective cohort studies aimed at examining associations between genetic markers, urinary (urine KIM-1 and NAG) and circulating (serum creatinine) markers of kidney injury. Once firmly established, the association of a particular genetic profile and outcome could be used to risk stratify patients for the development of ARF (fig. 4). Ultimately, cytokine-modulating therapies could be employed on the basis of genotypic risk stratification with the goal to prevent kidney injury or minimize its deleterious effects on patient outcome.